Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Use of corticosteroids in tuberculous meningitis

Tuberculous meningitis, the most devastating complication of tuberculosis, is a leading cause of death among children with tuberculosis. Those surviving tuberculous meningitis frequently have serious neurological disabilities. This consequence was noted by many early researchers soon after chemotherapy was introduced; Fitzpatrick in 19541 reported the outcome of tuberculous meningitis among patients treated in Denver receiving streptomycin, para-aminosalicylic acid, and isoniazid, the most efficacious regimen then available.